CLYBL is a human mitochondrial enzyme of unknown function that is found in multiple eukaryotic taxa and conserved to bacteria. The protein is expressed in the mitochondria of all mammalian organs, with highest expression in brown fat and kidney. Approximately 5% of all humans harbor a premature stop polymorphism in CLYBL that has been associated with reduced levels of circulating vitamin B12. Using comparative genomics, we now show that CLYBL is strongly co-expressed with and co-evolved specifically with other components of the mitochondrial B12 pathway. We confirm that the premature stop polymorphism in CLYBL leads to a loss of protein expression. To elucidate the molecular function of CLYBL, we used comparative operon analysis, structural modeling and enzyme kinetics. We report that CLYBL encodes a malate/b-methylmalate synthase, converting glyoxylate and acetyl-CoA to malate, or glyoxylate and propionyl-CoA to b-methylmalate. Malate synthases are best known for their established role in the glyoxylate shunt of plants and lower organisms and are traditionally described as not occurring in humans. The broader role of a malate/b-methylmalate synthase in human physiology and its mechanistic link to vitamin B12 metabolism remain unknown.
INTRODUCTION
Vitamin B12, or cobalamin, is an essential cofactor required for the activity of two human enzymes: mitochondrial methylmalonyl-CoA mutase (MUT) and cytoplasmic methionine synthase (MTR). Humans obtain cobalamin from diet or supplements, and once absorbed, the vitamin is further processed to its active forms-adenosylcobalamin for MUT and methylcobalamin for MTR. Vitamin B12 metabolism and utilization have been extensively studied, and with the exception of the mitochondrial transporter, the molecular identities of all proteins necessary for B12 maturation have been identified (1, 2) . Two recent human genetic association studies have begun to define the genetic loci that control B12 levels (3, 4) . Of the 12 non-intergenic loci collectively identified by these two studies, 11 lie near genes with established or purported roles in vitamin B12 biology, including B12 absorption (MS4A3, FUT2, FUT6, TCN1, TCN2, CUBN, CD320), B12 maturation (ABCD4, MMAA, MMACHC) and B12-dependent catalysis (MUT). The
12
th locus corresponds to a stop polymorphism within CLYBL, an uncharacterized protein. The B12-associated polymorphism (rs41281112) changes Arg259 to a stop codon, predicted to produce a truncated CLYBL protein. Notably, this polymorphism had the largest effect on B12 levels of all the SNPs reported: Chinese men homozygous for the premature stop had 3-fold reduced concentrations of circulating B12, with heterozygotes exhibiting an intermediate phenotype (3) .
Although CLYBL appears to be a metabolic enzyme, its activity remains entirely unknown. CLYBL is annotated as 'citrate lyase beta like' because it shows sequence similarity to citE, a component of an enzymatic complex (citE/citD/citF) found in bacteria that cleaves citrate to oxaloacetate and acetyl-CoA (ACoA) (5, 6) . All three subunits are necessary for complete lyase activity and often co-occur in the same operon (6, 7) . Humans, as well as other eukaryotes and certain bacteria and archea, possess homologs of citE but not of citD or citF, hinting at an alternate function for this gene (7) . Moreover, citrate cleavage in humans is mediated by the cytosolic, ATP-dependent ATP citrate lyase (8) . Although the crystal structures of citE homologs in certain organisms lacking citD and citF have been elucidated, the enzymatic function remains unknown.
CLYBL is among a growing number of human genes that harbor polymorphic loss-of-function (LOF) mutations in seemingly healthy individuals. Recent exome sequencing studies indicate that a typical human genome will harbor 150 LOF variants (9, 10) . The physiology of some LOF-tolerant genes is well studied, including mitochondrial ALDH2, which is associated with 'flushing' in response to alcohol (11, 12) , and G6PD, deficiency of which confers protection against malaria (13) . Many other LOF-tolerant genes, like CLYBL, remain poorly understood, but if investigated, could yield valuable insights into gene-environment interactions, potential sites of natural selection and novel drug targets.
Here, we explore the molecular function of CLYBL. Using comparative genomics, structural homology modeling and enzymology, we narrowed the list of potential enzymatic activities for CLYBL. We report that CLYBL exhibits malate synthase and b-methylmalate synthase activities, which have never before been reported for a human protein.
RESULTS

CLYBL domain organization, subcellular localization and tissue expression
Human CLYBL is 340 amino acids in length and includes a canonical amino-terminus mitochondrial targeting sequence (MTS, Fig. 1A ). It is ubiquitously expressed in mitochondria from all mammalian tissues (14) . Adjacent to its MTS, CLYBL contains one Pfam domain, the HpcH/HpaI aldolase/citrate lyase family domain (15) , which is the basis for the gene's name (citrate lyase beta like).
We examined RNA profiles from 91 tissues and cell types, primarily from C57BL/6 adult male mice, measured with Affymetrix MOE430_2 microarrays (16) , as well as protein expression profiles across 28 mouse tissues from wild-type C57BL/6 adult mice (17) . Focusing on the 18 tissues common to both datasets, we observed that Clybl expression was highest in brown fat and kidney (Fig. 1B) .
Impact of the rs41281112 polymorphism on CLYBL expression
The loss-of-function polymorphism (rs41281112) changes Arg259 to a premature stop. Out of the 1092 individuals included in the 1000 Genomes Project Phase 1 data, two individuals-one European and one East Asian-were homozygous null for CLYBL (rs41281112), and 49 individuals were heterozygous. The allele frequency varies among populations-5.8% in Europeans, 7.7% in East Asians, 2.8% in Admixed Americans and 0% in Africans (9) . Not included in Phase 1 but part of the larger 1000 Genomes Project, we identified a trio with a segregating rs41281112 polymorphism (father homozygous for the predicted LOF T|T genotype, mother homozygous for the wildtype C|C genotype and heterozygous daughter) (Fig. 1C) . At both the mRNA (Fig. 1D) and protein ( Fig. 1E ) levels, the father exhibited the lowest expression of CLYBL, while the heterozygous daughter had an intermediate phenotype. These results demonstrate that the predicted LOF polymorphism does indeed lead to loss of the protein product.
Co-evolution and co-expression of CLYBL with mitochondrial B12 metabolism
To better understand the function of CLYBL, we considered genes that are co-evolved and co-expressed with CLYBL. First, we performed a phylogenetic profiling analysis of CLYBL, using a new tree-based method (Y. Li et. al., manuscript in review). We utilized a previously published eukaryotic tree of life (10) , and used this new algorithm to infer the ancestral states for CLYBL ( Fig. 2A) . We then scored all human proteins for the likelihood of having evolved under the inferred model of CLYBL evolution compared with a random model. This genome-wide analysis spotlighted nine proteins with a positive log-likelihood ratio (LLR), including all mitochondrial vitamin B12 processing and utilization components (MMAA, MMAB, MUT).
We next sought to identify mouse genes co-expressed with CLYBL at the RNA and protein levels. We calculated Pearson's correlation values for co-expression of CLYBL with all other genes, and found that at both the RNA and protein levels, only a small number of genes were highly correlated with CLYBL, including Mut, Mmaa and Mmab (Fig. 2B,C) . We found that Mmaa and Mmab were highly correlated (Pearson's correlation coefficients .0.9 for RNA and protein) with Mut not far behind (Pearson's correlation coefficient .0.7 for RNA and .0.8 for protein). Among these highly correlated gene products, we also found the alpha and beta subunits of propionyl-CoA carboxylase (PCCA, PCCB), the alpha and beta subunits of methylcrotonyl-CoA carboxylase (MCCC1, MCCC2) and methylmalonyl-CoA epimerase (MCEE). We sought to determine whether the observed correlation represented a simple consequence of the fact that mitochondrial proteins tend to be co-expressed with each other (18) . Even among genes encoding mitochondrial proteins, we observed that the mitochondrial vitamin B12 processing proteins are among the most closely correlated to CLYBL (Fig. 2B,C) .
These genome-wide co-evolution and co-expression analyses (Fig. 2) strongly support a functional link between CLYBL and mitochondrial B12 metabolism, in further support of the human genetic association studies (3, 4) .
Operon analysis of bacterial homologs of CLYBL
CLYBL is annotated as 'citrate lyase beta-like' due to sequence similarity to bacterial citE, which specifically performs the citrylacyl carrier protein cleavage step of the citrate lyase reaction. CLYBL is unlikely to have the same function because bacterial citE requires two additional proteins, citD and citF, to perform the citrate lyase reaction, and these proteins are not found in humans (7) .
We sought to determine whether bacterial CLYBL homologs always co-occur with citD and citF. Of 942 diverse bacterial species represented within the Cluster of Orthologous Groups (COGs) database (19), we found that 121 contain CLYBL homologs as well as citD/citF homologs, while 281 species contain CLYBL homologs but lack citD/F homologs (Fig. 3Ab) .
To predict eukaryotic CLYBL's function, we focused on CLYBL homolog-containing operons within the 281 bacterial species lacking citD/F homologs. These 587 CLYBL-containing operons comprised a total of 3947 different genes, corresponding to 576 unique COGs. Interestingly, no single operon structure was overrepresented. However, the top 10 COGs that co-occurred with CLYBL included 3 involved in acyl CoA reactions, 2 with ACoA metabolism, 2 with propionate/propionyl-CoA (PCoA) catabolism and 1 with malate/lactate metabolism (Fig. 3B) .
In a few instances, bacterial CLYBL homologs found in operons lacking citD/F have been characterized at the structural and biochemical levels. The structures of RipC from Yersinia pestis KIM 10 (biovar Mediaevalis) (20) and CitE from Mycobacterium tuberculosis H37Rv (7) have been elucidated, but the enzymatic activities have not been tested. Mcl1 and Mcl2 are homologs of CLYBL in Rhodobacter sphaeroides strain 2.4.1 (21) and operate together to produce malate synthase activity. With the exception of Mcl1, which appears in an operon on its own, the rest of these genes appear in operons with genes in COGs similar or identical to those shown in Figure 3B . In particular, all the three operons contained enzymes predicted to be involved in acyl-CoA metabolism.
Enzymatic activity of CLYBL
Based on the above comparative operon analysis, the reported biochemical activity observed in R. sphaeroides, and published crystal structures (7, 20, 21) , we hypothesized that the human CLYBL might perform similar catalytic reactions. Therefore, we designed, bacterially expressed, and purified human CLYBL with an N-terminal His-tag, but without the predicted MTS (22) . We used Ellman's reagent (DTNB) to monitor the production of CoA-SH in the presence of pairs of substrates: (i) an acyl-CoA coupled with (ii) either glyoxylate or a larger alpha-ketoacid. Our assay was based on a previously reported assay for malate synthase activity (23), though using potassium phosphate buffer to avoid glyoxylate complexation (24) . We tested CLYBL with a variety of pairs of substrates, including ACoA, PCoA, butyrylCoA or racemic methylmalonyl-CoA, coupled with glyoxylate, pyruvate, 2-oxobutyrate or alpha-ketoglutarate. CLYBL only showed substantial activity when incubated with glyoxylate and either ACoA or PCoA, reactions predicted to produce malate and b-methylmalate, respectively. CLYBL also showed some activity, though lower, when incubated with ACoA and pyruvate, a substrate pair predicted to produce citramalate. As a positive control, we also tested GlcB, a previously characterized malate synthase from M. tuberculosis (25) . We expressed and purified GlcB in Escherichia coli, in parallel with CLYBL, and found that GlcB was specific for ACoA/glyoxylate and had kinetic values in our assay on par with those reported in the literature (unpublished data), demonstrating the fidelity of our assay.
A CoA-SH-producing reaction between glyoxylate and ACoA appeared most likely to be a malate synthase reaction (Fig. 4A ), so we further characterized this activity. We found that our recombinant protein had an apparent K m of 3.6 mM for glyoxylate and 74 mM for ACoA, similar to the K m s observed for the condensation of ACoA and glyoxylate by R. sphaeroides Mcl1, though Mcl1 does not perform the complete malate synthase reaction, instead producing malyl-CoA, which is cleaved to malate and CoA by Mcl2. CLYBL had a maximum specific activity of 180 pmol/mg protein/minute, and a turnover per subunit of 0.12 s
21
, slow compared with Mcl1 at 8.6 s
. Other divalent cations can substitute for magnesium in this reaction, but CLYBL has essentially no activity in the presence of EDTA or Ca 2+ (Table 1 ; Supplementary Material, Table S1 ). We confirmed that CLYBL indeed produced malate by monitoring malate production over time via liquid chromatography/ mass spectrometry (LC/MS) (Fig. 4B) . We confirmed the identity of malate as the reaction product by matching its retention time, exact mass and MS/MS spectra to a standard (Fig. 4B , inset). After confirming that our method could linearly detect increasing concentrations of malate standard doped into the reaction mix, we monitored the progress of the reaction over 30 min with or without the addition of 1 mg CLYBL. We observed malate accumulation only in complete reaction mixtures containing CLYBL.
We also characterized the CLYBL-catalyzed reaction coupling glyoxylate and PCoA to produce CoA-SH, which was mostly likely producing b-methylmalate (Fig. 4C) . We observed an apparent K m of 1.2 mM for glyoxylate and 23 mM for PCoA, similar to those observed for condensation of PCoA and glyoxylate to b-methylmalyl-CoA by R. sphaeroides Mcl1. This Rhodobacter protein is unable to perform the complete b-methylmalate synthase reaction, and Mcl2 has not been shown to cleave b-methylmalyl-CoA (21). CLYBL had a maximum specific activity of 138 pmol/mg protein/minute, and a turnover per subunit of 0.09 s
, slow compared with Mcl1's condensation of the same substrates (Supplementary Material, Table S1 ). We confirmed the identity of b-methylmalate as our reaction product using the LC/ MS retention time, exact mass and MS/MS spectra to compare the product with a standard (Fig. 4D, inset Table S1 ).
Structural homology modeling of CLYBL
We sought to determine whether the modeled structure of CLYBL is compatible with the malate synthase and b-methylmalate synthase activities. We modeled the structure of CLYBL using as templates the 1.65 Å resolution structure of citrate lyase beta subunit from M. tuberculosis (PDB 1u5h) (7) and the 1.95 Å resolution structure of Haloferax volcanii malate synthase complexed with ACoA, pyruvate and Mg 2+ (PDB 3oyz) (26) . Using a multistep procedure involving structure-based sequence alignment (Materials and Methods), a model with good geometry was obtained for residues 42-285 of CLYBL despite only 17% amino acid sequence identity with the template. The C-terminal 55 amino acid segment could not be modeled because the corresponding structure in the template (1u5 h) was missing.
Importantly, due to the presence of ACoA and a substrate analog (pyruvate) in the template structure, the role of several conserved residues critical for the catalytic activity of CLYBL can be evaluated based on the model. The protein has a (b/a) 8 TIM barrel fold common to a large group of enzymes, including malate synthases (27) (28) (29) . In this fold, the substrate-binding sites are made of variable loops that connect the C-termini of parallel b-strands with adjacent a-helices. The key element of the catalytic center is Mg 2+ coordinated in octahedral geometry by two oxygen atoms of the substrate (glyoxylate), the side chain oxygen atoms of Glu171 and Asp206, and two H 2 O molecules. Glu75 and Asp76 further stabilize the complex via hydrogen bonds to Mg 2+ -bound H 2 O molecules. An essential element of the catalytic center is Arg107, whose side chain guanidinium group makes strong hydrogen bonds simultaneously with the alpha oxygen of glyoxylate and the acetyl carbonyl oxygen atom of ACoA, thus positioning these substrates precisely for catalysis (Fig. 5) . It is also apparent from the model that substitution of a propionyl group for the acetyl group of ACoA can be readily accommodated without affecting any of the key interactions, explaining CLYBL's ability to act as a b-methylmalate synthase as well as a malate synthase.
All the important elements of the catalytic center of CLYBL discussed above are also present in other malate synthase structures and are consistent with CLYBL having a malate synthase catalytic activity. However, in all the three types of malate synthases (A, G and H), there is a C-terminal extension, which apparently plays an important role in catalysis. Specifically, the side chain of Asp633 in M. tuberculosis malate synthase isoform G was proposed to function as a catalytic base that abstracts a proton from ACoA (25) . Substitution of Asn for Asp631, the corresponding residue in E. coli malate synthase, renders the protein inactive (24) . There is a conserved Asp residue at the structurally equivalent position also in A and H isoforms of malate synthase (26, 31) . The absence of an equivalent structural element in the CLYBL monomer may contribute to the low observed catalytic activity. With the structural model in hand, we sought to further confirm that CLYBL had malate synthase and b-methylmalate synthase activities by mutating specific residues predicted to be critical for various aspects of catalysis. Based on homology modeling and evolutionary conservation, we mutated residues Glu75 and Glu171, predicted to be important for coordinating a magnesium-binding water molecule and directly binding magnesium, respectively, to Gly and found that these mutants had no malate synthase or b-methylmalate synthase activity in our DTNB-linked assay (data not shown). We also mutated Asp250 to Gly to evaluate the effect of a charge mutation at a residue that is conserved but distal to the active site, and found that this mutation reduced but did not eliminate these activities (data not shown). We also attempted to express and purify the Arg259Stop LOF variant (Fig. 1A,C-E) identified from the 1000 Genomes data and associated with low circulating B12 levels, but the expressed protein was insoluble, suggesting that the human mutant may be improperly folded if it is expressed at all, consistent with what we observed in cell lines from individuals with the premature stop polymorphism (Fig. 1E) .
DISCUSSION
Our computational, enzymatic and structural homology analyses demonstrate that purified recombinant CLYBL possesses malate synthase and b-methylmalate synthase activities, which, to our knowledge, is the first time that such activities have been ascribed to a human protein. Malate synthase is traditionally described as operating in alternative carbon assimilation pathways such as the glyoxylate shunt. At present, the link between CLYBL and circulating B12 levels remains unclear, but it is notable that the newly identified substrates and products of CLYBL, as well as gene products strongly co-expressed with and co-evolving with CLYBL ( Fig. 2) , lie in close proximity to the mitochondrial B12 pathway (Fig. 6) .
It is important to consider the kinetic parameters of CLYBL in the context of previously reported malate synthases. Previously studied malate synthase enzymes vary widely in their affinity for glyoxylate, ranging from a K m of 2 mM in Ricinus comunis (32) to 21 mM in E. coli (24) . The 3.6 mM K m reported here is at the high end of this spectrum, but it is similar to the 3.1 mM K m reported for Mcl1 in R. sphaeroides (Table 1 (21) . It is important to note that in our assays CLYBL is relatively inefficient, with low specific activity, but it could be the case that CLYBL requires an additional protein partner or post-translational modification in vivo to enhance its activity. When we screened possible substrate pairs, we noted that CLYBL had low activity with pyruvate and ACoA too, suggesting that it has low citramalate synthase activity. It is possible that CLYBL has additional enzymatic activities with greater catalytic efficiency that have not been tested here.
We note in our structural modeling that CLYBL is missing a large C-terminal domain present in malate synthase enzymes. Critically, CLYBL is missing a conserved aspartate (Asp633 in M. tuberculosis malate synthase G) predicted to work as a catalytic base that abstracts a proton from ACoA to initiate the malate synthase reaction (25, 26 ). An Asp residue in a structurally equivalent position is absolutely conserved in all G form ( 730 amino acids) malate synthases as well as in their shorter analogs: the A form ( 530 amino acids), e.g. the E. coli and B. anthracis malate synthases (31) and the H form ( 430 amino acids), e.g. H. volcanii (26) . Substitution of this critical Asp with Asn in the E. coli G malate synthase was shown to render the protein inactive (24) . Thus, a question arises which, if any, part of CLYBL could substitute for the missing catalytic Asp. A comparison of our model of CLYBL with the template H. volcanii malate synthase indicates that the C-terminal 50 amino acid segment of the polypeptide chain, which we were unable to model due to the low sequence similarity, is too short to fold into a stable structure required for positioning the critical Asp close to the bound substrate within the same monomer. We hypothesize that this critical contribution must be provided by intermolecular interactions within an oligomeric structure. Strong support for this prediction comes from the structure of the putative citrate lyase beta subunit from B. xenovorans (PDB 3r4i). The 339 amino acid polypeptide chain of this protein folds into a TIM barrel structure like CLYBL, but also contains a small flexible C-terminal domain, which extends into the catalytic domain of the neighboring Figure 6 . Newly identified enzymatic activities of CLYBL in the context of mitochondrial B12 metabolism. Genes in light blue encode enzymes in the mitochondrial B12 pathway. Genes in magenta encode transcripts and proteins that are highly co-expressed with CLYBL. Solid lines indicate one-step reactions and dashed lines represent multiple enzymatic steps. monomer in the biological trimer (Supplementary Material, Fig.  S1A ). Asp298 in that domain is exactly in the same position as the catalytic Asp388 of H. volcanii malate synthase (Supplementary Material, Fig. S1B ). Based on the amino acid sequence alignment (using MUSCLE) of CLYBL and B. xenovorans citrate lyase, we tentatively identify Asp320 as the plausible catalytic residue in CLYBL (Supplementary Material, Fig. S2 ) (33) . Interestingly, other citrate lyase beta proteins are trimers based on their X-ray structures, suggesting that these proteins might also have malate synthase activity. Further studies are needed to verify this prediction.
Malate synthases are traditionally described as part of alternative carbon assimilation pathways. Malate synthase and isocitrate lyase together comprise a glyoxylate shunt that bypasses two CO 2 -releasing steps of the TCA cycle (34) to promote biomass accumulation from lipids without the loss of carbon. Malate synthase activity can occur in organisms lacking isocitrate lyase (21) and is thought to function in an acetate assimilation ethylmalonyl-CoA pathway (21, 35, 36) . In principle, CLYBL could be participating in a similar carbon assimilation pathway. Malate synthase and isocitrate lyase activities have been reported in brown adipose tissue from black bears (37), livers of several mammals (38 -40) and toad bladder (41), though other groups have disputed these results (42, 43) . In none of these reports was a molecular basis for these activities identified. In light of these previous studies, it is notable that CLYBL expression is particularly high in brown fat (Fig. 1B) .
The b-methylmalate synthase activity of CLYBL may be particularly important in the context of certain inborn errors of metabolism, which are characterized by elevated PCoA (44) . In such disorders, it is known that PCoA can compete with ACoA to produce side products, such as methylcitrate (45) . It is conceivable that b-methylmalate is similarly produced by CLYBL. Whether b-methylmalate is a toxic metabolite, or perhaps an inert metabolite that is excreted, remains to be determined.
Our work adds CLYBL to the growing number of human enzymes known to utilize glyoxylate, and underscores a broader role for this metabolite in human physiology. Glyoxylate is best studied in the context of calcium oxalate stones that are due to mutations in AGXT or GRHPR (46) . Previous studies have suggested that the intracellular concentration of glyoxylate ranges between 0 and 100 mM (47, 48) , though these estimates may be low relative to concentrations within subcellular compartments (49) . Glyoxylate in humans may originate from the diet, via glycolate in vegetables and hydroxyproline in meat (50) . It may also come from the enzymatic activities of glyoxylate reductase, lactate dehydrogenase (51) or alanine:glyoxylate aminotransferase (52) .
Our work provides unequivocal support for a physiological link between CLYBL and B12 metabolism. We have shown that CLYBL is strongly co-expressed with and co-evolving with all the three known members of the mitochondrial B12 pathway: MUT, MMAA and MMAB (Fig. 2) . These analyses complement previous association studies that found the CLYBL LOF polymorphism was associated with low B12 levels in human plasma (3, 4) . In the current work, we have shown that this polymorphism leads to a loss of the CLYBL protein (Fig. 1E) . It is notable that the substrates and products of malate/b-methylmalate synthase lie within close metabolic proximity to the mitochondrial B12-dependent enzyme MUT (Fig. 6) . Why polymorphisms in MUT and CLYBL alter circulating B12 levels is not known. One possibility is that B12 levels are regulated by sensing the substrates/products of the reactions in Figure 6 , analogous to other human metabolic pathways (53) .
Although our work has been focused on human CLYBL, it has potential implications for the development of novel therapeutics for M. tuberculosis. While the crystal structure of the M. tuberculosis CLYBL homolog, CitE (accession Rv2498c), has been solved, its enzymatic activity has remained enigmatic (7). We hypothesize that this protein has the same activity as CLYBL, and it would be straightforward to screen for inhibitors of the protein using the assays we have developed. Mycobacterium tuberculosis malate synthase GlcB is already being pursued as an anti-tuberculosis drug target (54), but if the CLYBL homolog is able to substitute for this enzyme, it may be crucial to target both enzymes. Any small-molecule inhibitors discovered would be particularly attractive candidates for therapeutic development; even if they also inhibited the human CLYBL, we would not expect overt toxicity, given that humans can evidently tolerate loss of CLYBL.
MATERIALS AND METHODS
Cellular studies
The following B-lymphocyte cell lines were ordered from the Coriell Cell Repository: HG01970 (T|T for rs41281112), HG01971 (C|C), HG01972 (C|T). Cells were cultured in Sigma RPMI 1640 with 2 mM glutamine, 15% Gibco 16000 fetal bovine serum at 378C. For mRNA expression analysis, mRNA was isolated from cells using a Qiagen RNeasy kit, and qRT-PCR was performed for CLYBL and ACTB using Taqman assays (Applied Biosystems, assay ID Hs00370518_m1 and 4352935E, respectively), according to the manufacturer's protocol. The qRT-PCR data are expressed as DDC T values with respect to ACTB and HG01971. For western blot analysis, whole cell lysates were prepared and resolved by SDS-PAGE followed by transfer to a PVDF membrane using the Trans-Blot Turbo Transfer System. Membranes were probed using a primary antibody for CLYBL (Abnova CLYBL MaxPab mouse polyclonal antibody H00171425-B01P, 1:500) or ATP5A (Abcam Mouse Monoclonal, no. AB14748, 1:50 000), followed by a secondary antibody (Polyclonal Sheep anti-IgG mouse antibody, no. NA931V, 1:10 000). The signal was detected using a Pierce ECL western blotting substrate.
Phylogenetic profiling
To study the evolutionary history of CLYBL, we utilized a phylogenetic profiling algorithm (Li et al., manuscript in review). The algorithm accepts as input a binary phylogenetic tree, a binary homology matrix and a query gene set G. It then partitions G into disjoint clusters in which genes share an inferred model of evolutionary history. For each cluster, the algorithm then identifies genes not in G but that share the same evolutionary history. A published phylogenetic tree (10) with 138 eukaryotic species and a single prokaryote outgroup, a phylogenetic matrix of 20 834 human genes, and CLYBL as a single gene in G were used as input. The human-centric phylogenetic matrix X ¼ {X g,s } 20834 × 138 was constructed to contain 1 if the human reference gene g shared sequence similarity to any protein in species s (BLASTP, Expect,1e23) and 0 otherwise. The algorithm estimated the evolutionary model of gain and loss events for CLYBL, and scored all other genes for the likelihood of having arisen under the same inferred model of evolution compared with the background null model, using an LLR. Genes with an LLR score exceeding threshold 0 were concluded to share the same history with CLYBL and included in the final output shown in Figure 2 .
Co-expression analysis
We analyzed publicly available RNA and protein expression data generated by Lattin et al. (16) and Geiger et al. (17) , respectively. In brief, Lattin et al. quantified the RNA expression of over 17 000 genes across 91 C57BL/6 mouse tissues or cell types using Affymetrix MOE430_2 microarrays. Geiger et al. quantified the expression of over 6900 proteins across 28 C57BL/6 mouse tissues using LC-MS/MS with mouse tissues labeled via stable isotope labeling with amino acids in cell culture (SILAC) as an internal standard. Pearson's correlations were calculated comparing Clybl RNA expression with those of all genes across the 18 mouse tissues (kidney was the average of two sections) in common with the protein dataset and comparing Clybl protein expression with those of all genes across the 28 mouse tissues in the protein dataset. Missing values in the protein expression dataset were ignored in the calculations, and if greater than half (14) of the values for a protein were missing, the protein was removed from the dataset. The mouse MitoCarta (14) was used to attain all genes encoding proteins with strong support of mitochondrial localization.
Bacterial operon analysis
Genomic data for 942 bacterial species were downloaded from eggNOG version 3.0 (19) . Consecutive genes on the same strand were annotated to reside in the same operon. Crossspecies homologs were determined using pre-computed COG assignments (eggNOG version 3.0), including annotation of homologs to CLYBL/citE (COG2301), citD (COG3052), and citF (COG3051). We identified the species that contained COG2301 but lacked COG3051 and COG3052. For these 281 species, we computed how many times each COG was present within an operon that also contained COG2301. We applied the same analysis to the 121 species that contained all three COGs: COG2301, COG3052 and COG3051.
Protein expression and purification
Starting with the full-length consensus sequence for CLYBL (CCDS32002.1), we removed the TargetP-predicted 22 amino acid targeting sequence and added a methionine to facilitate future cloning and expression of a C-terminally tagged protein (22) . The sequence was codon-optimized for bacterial expression, synthesized with 5 ′ Sal1 and 3 ′ Xho1 restriction sites and cloned into pUC57-Kan by Genewiz. The construct was digested with BamH1 and EcoR1 (NEB) and ligated into the pET-30a(+) vector, in frame with the N terminal 6×His tag, using NEB T4 DNA ligase. After sequence verification, the protein was expressed with Invitrogen One Shot BL21 Star (DE3) chemically competent E. coli cells grown at 378C shaking at 225 rpm.
Cultures (OD 600 0.4 -0.7) were induced with 1 mM IPTG and grown overnight at 158C before harvest.
The purification protocol was a modified version of previous protocols for recombinant malate synthase purification (24) . We resuspended pelleted bacteria in 50 mM HEPES pH 7.9, 300 mM NaCl, 10% glycerol, 10 mM MgCl 2 , supplemented day of use with 3 mM 2-mercaptoethanol and Roche cOmplete mini EDTA protease inhibitor tablets. Cells were lysed with a sonicator (1 s on, 1 s off, 30% intensity × 15 × 3). Lysate was cleared by spinning in a JA20 centrifuge at 19 500 rpm for 30 min at 48C. Clear lysate was incubated with pre-washed GE Ni-Sepharose 6 fast flow resin for 1 h at 48C, then washed with wash buffer (50 mM Hepes, 300 mM NaCl, 20 mM imidazole, pH 7.8, 10 mM MgCl 2 ). Protein was eluted with elution buffer (50 mM HEPES pH 7.8, 300 mM NaCl, 500 mM imidazole, 10 mM MgCl 2 , 3 mM betamercaptoethanol) and dialyzed at 48C using Thermo Pleated Snakeskin Dialysis Tubing (2 × 1.5 h) into 25 mM potassium phosphate pH 8.0 for enzymatic assays. Protein was dialyzed in 20 mM Tris pH 7.8 for ion screening. Protein concentration was determined using the Pierce BCA protein assay.
A similar method was used for gene synthesis and expression of M. tuberculosis malate synthase GlcB. QuikChange Lightning mutagenesis was used to modify specified residues in the CLYBL bacterial expression construct.
Enzymatic activity assays
Chemicals and reagents were purchased from Sigma, with the exception of b-methylmalate from Otava Ltd. The production of CoA-SH from ACoA or PCoA in response to glyoxylate was monitored spectrophotometrically at 412 nm (378C) in the presence of 100 mM DTNB (23) . The assay used 1 -10 mg of recombinant protein per well in 96 well format. Protein was resuspended in an assay mix composed of 50 mM potassium phosphate monobasic, 10 mM MgCl 2 , and 2 mM EDTA, pH 8.0, plus 500 mM final concentration of the CoA of interest. The reaction was mixed and monitored for 2 min before the addition of 10 mM glyoxylate (prepared fresh each time). Activity was determined by subtracting the slope pre-glyoxylate addition from the slope post-glyoxylate addition, converting the change in absorbance at 412 nm to moles of SH product (and thereby to moles of acyl-CoA) using the extinction coefficient of 14 150 M 21 cm 21 for DTNB and the 0.585 cm path length specified for our 96 well plates.
K m values were calculated by varying the concentrations of acyl-CoA and glyoxylate; divalent ion selectivity was determined by replacing 10 mM MgCl 2 with 10 mM MnCl 2 , CaCl 2 , CoCl 2 , or NiCl 2 , or 20 mM EDTA, in a reaction mix composed of 10 mM glyoxylate, 300 mM acyl-CoA, and 20 mM Tris buffer (pH 7.8) instead of potassium phosphate to avoid precipitation.
Mass spectrometry
To confirm the identity of the non-CoA-SH product in each reaction, we used LC/MS-MS. Recombinant protein (1 mg per 50 ml final reaction) was incubated in 20 mM Tris pH 7.8, 10 mM MgCl 2 , 2 mM EDTA and 300 mM of either ACoA or PCoA. Reactions were initiated with 10 mM glyoxylate, mixed and incubated at 378C, then quenched 1:1 (v/v) with HPLC-grade methanol at the indicated time point. Malate or b-methylmalate standard curves were run in a pre-quenched reaction mix. Samples were kept in a sealed 384-well plate at 48C until analysis (within 24 h).
Samples were injected into a Phenomenex Luna 3 mm NH2 100 Å 150 × 2.00 mm column eluted at 0.2 ml/min. Samples were eluted over a 55 s ramp from 10 to 100% A (20 mM ammonium hydroxide, 20 mM ammonium acetate in water), followed by 2 min at 100% A, a 1 min ramp back to 10% A, and 2 min of re-equilibration at 10% A. Mobile Phase B was 75:25 v/v acetonitrile/methanol with 20 mM ammonium hydroxide (55) . Data (negative ion mode) were collected with a Q Exactive mass spectrometer (Thermo Scientific) using the following parameters: sheath gas flow rate 45, auxiliary gas flow rate 15 
Structural modeling
Modeling of human CLYBL 3D structure (Q8N0X4-1) was performed using the Swiss Model server (http://swissmodel.expasy. org/) (56) (57) (58) . The model was built in several steps. First, we used the Basic Local Alignment Search Toll (BLAST) available via NCBI server (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to identify the proteins in PDB whose amino acid sequences are most closely related to the fragments 23-340 of CLYBL (the N-terminal MTS deleted). The highest scoring proteins (28-34% sequence identity) were those annotated as citrate lyase beta subunits. The highest scoring structure of a malate synthase was that from H. volcanii (PDB 1oyx). However, with only 17% sequence identity this template proved unsuitable for direct modeling due to uncertainty in sequence alignment. Thus, the structure of citrate lyase from M. tuberculosis (PDB 1u5 h) (7) that had the highest resolution (1.65 Å ) was selected as a template. This yielded an initial model of CLYBL (Model1), which featured a characteristic (b/a) 8 TIM barrel fold common to a large group of enzymes including malate synthases. Then we used the PDBe Fold server at the European Bioinformatics Institute http:// www.ebi.ac.uk/msd-srv/ssm/cgi-bin/ssmserver (59) to structurally align CLYBL Model1 with several citrate lyase betas and malate synthases, which revealed strict conservation of residues considered critical for catalysis. With the amino acid sequence alignment from PDBe Fold we have modeled CLYBL using as a template the 1.95 Å resolution structure of H. volcanii malate synthase ternary complex with ACoA and pyruvate (PDB 3oyz) (26) . The obtained model (Model 2) had a good geometry despite only 17% sequence identity with the template. Finally, coordinates of ACoA, glyoxylate (in place of pyruvate) and Mg 2+ ions with two coordinating H 2 O molecules from 3yoz were combined with Model 2 using COOT (60, 61) . Only minor adjustments of rotamers for a few side chains were required. In the final model of CLYBL, all the amino acids important for catalysis were found in the correct positions for the interaction with substrates, including the octahedral coordination of Mg 2+ essential for catalysis. All URLs were last accessed December 18, 2013. Structures were visualized in PyMOL (30) .
NOTE ADDED IN PROOF
Subsequent to the submission of this work, Zarzycki and Kerfeld (62) reported the X-ray structures of two malyl-CoA lyases (MCL), bacterial proteins homologous to human CLYBL. Zarzycki and Kerfeld reported that the active form of MCL is a dimer of trimers, in which a flexible C-terminal domain complements the active site of an adjacent molecule in the trimer, providing a critical aspartate for catalysis. This residue corresponds to Asp320 of CLYBL, which we have predicted to serve this same function (see Discussion).
